Cencora stock gains as specialty strategy supports fiscal 2027 outlook
Published on 09/22/2026 at 02:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora, Inc. stock (ISIN US03073E1055) is trading near recent highs as investors react to the company’s emphasis on specialty distribution and services that are expected to support growth into fiscal 2027, backed by solid revenue and earnings trends in its latest fiscal year 2025 figures.
Specialty push and fiscal 2027 growth narrative
As MarketBeat reported on September 21, 2026, Cencora highlighted that its specialty-focused strategy is expected to fuel growth into fiscal 2027, underscoring the role of specialty pharmaceutical distribution and related services in its long-term plan.
In a separate conference-related update, MarketBeat noted on September 21, 2026 that Cencora emphasized specialty growth, expansion of its management services organization (MSO) offerings and ties with Walgreens, reinforcing that specialty services, manufacturer support and patient-centered solutions are central to its revenue mix.
Recent fundamentals frame the growth story
Per data shown in the Cencora profile on Reuters, Cencora generated revenue of about USD 321,332.82 million in fiscal year 2025, up from roughly USD 293,958.60 million in fiscal year 2024, which represents an increase of approximately 9.3 percent and illustrates the scale of its distribution operations.
The same Reuters-based overview indicates that Cencora’s net income in fiscal year 2025 was approximately USD 1,554.17 million compared with about USD 1,509.12 million in 2024, marking a year-over-year gain of around 3.0 percent and showing that profits also expanded, albeit more modestly than revenue.Reuters
The fiscal 2025 figures summarized in the Reuters profile also show gross profit of about USD 11,291.74 million versus USD 9,793.21 million in fiscal 2024, an increase of roughly 15.3 percent, suggesting that Cencora’s profitability on its large revenue base improved over the period.Reuters
Earnings trends and margin context
According to the detailed statistics shown on Yahoo Finance, trailing twelve-month earnings per share (EPS) for Cencora stand at 13.46 dollars, providing a snapshot of the company’s profitability per share based on its most recent four quarters.
The same Yahoo Finance overview displays that Cencora reported revenue of around USD 84.75 billion in its third quarter of fiscal year 2026 with earnings of about USD 763.52 million for that quarter, alongside a profit margin of approximately 0.90 percent, underlining the company’s volume-driven business model where margins are thin but supported by very high turnover.Yahoo Finance
Yahoo Finance’s earnings section also lists an estimate EPS figure of 4.35 dollars for Cencora’s third quarter of fiscal 2026 and an actual EPS of 4.48 dollars, indicating that the company exceeded that quarterly EPS estimate by 0.13 dollars, a modest but positive surprise that supports the specialty growth narrative.Yahoo Finance
Outlook, risks and investor perspective
The news flow compiled on Yahoo Finance shows that Cencora has recently raised its 2026 EPS outlook while continuing a share buyback program, reinforcing management’s confidence in specialty businesses and capital allocation, although the exact EPS guidance figures are not broken out in detail in that summary.
The same Yahoo Finance news overview points to commentary that Cencora’s stock has moved higher since its last earnings report and that specialty businesses are strengthening, but it also implicitly highlights the structural risk of operating in a low-margin, high-volume pharmaceutical distribution environment where a profit margin around 0.90 percent in Q3 fiscal 2026 leaves limited room for operational missteps.Yahoo Finance
Stock price level and trading context
Per recent data shown on Yahoo Finance, Cencora stock last closed at 308.78 dollars on the New York Stock Exchange on September 18, 2026, unchanged intraday aside from a small move to 308.76 dollars in after-hours trading, which places the shares close to their recent range and reflects the market’s measured response to the specialty-focused growth narrative.Yahoo Finance
Cencora stock facts
- Company: Cencora, Inc.
- ISIN: US03073E1055
- Ticker: COR
- Trading venue: NYSE
- Price (as of September 18, 2026, 16:00): 308.78 USD
- Market capitalization: [value not substantiated] USD (as of [date not substantiated])
- Sector / Industry: Healthcare / Pharmaceutical distribution
- Index membership: S&P 500
